Evolution of Metabolic Syndrome in Newly Diagnosed Type 2 Diabetes Mellitus Asian-Indian Patients Over the Last 15 Years using Adult Treatment Panel III of the National Cholesterol Education Program, World Health Organization, and International Diabetes Federation Criterion.


Journal

The Journal of the Association of Physicians of India
ISSN: 0004-5772
Titre abrégé: J Assoc Physicians India
Pays: India
ID NLM: 7505585

Informations de publication

Date de publication:
Jun 2024
Historique:
medline: 17 6 2024
pubmed: 17 6 2024
entrez: 17 6 2024
Statut: ppublish

Résumé

A retrospective observational study was undertaken to assess the changing trends in the incidence of metabolic syndrome (MetS) in Asian-Indian patients with newly diagnosed type 2 diabetes (T2D) using Adult Treatment Panel III of the National Cholesterol Education Program (NCEP-ATP III), World Health Organization (WHO), and the International Diabetes Federation (IDF) criteria. The overall and gender-wise pattern of MetS and its components were also evaluated. Newly diagnosed T2D patients ( In the current study, the overall incidence of MetS observed among the study population was 80.9, 65.4, and 69.8% using NCEP-ATP III, WHO, and IDF criteria, respectively. The incidence of MetS across the three timelines (i.e., from 2004 to 2019) with all the diagnostic criteria showed a steady increase. An analysis of the individual components of MetS revealed a high incidence of central obesity across all subgroups, followed by hypertension and dyslipidemia. Central obesity was prevalent in nearly 85.9% of patients in 2014-2019 vs 78.6% in the 2004-2008 subgroup. Similarly, the incidence of hypertension and overall dyslipidemia [i.e., high triglycerides (TGs) and low high-density lipoprotein-cholesterol (HDL-C)] was 77.8% and 68.2% in the former vs 67.9% and 59.6% in the latter, respectively. The incidence of all three MetS components, along with fasting sugar, showed a statistically significant and progressive increase over the years, with prevalence in group III (2014-2019) being the highest. Women were found to be more centrally obese and more dyslipidemic compared to men, whereas men were found to be more hypertensive. The study shows a high incidence of MetS in Asian-Indian patients with newly diagnosed T2D. The incidence of MetS was significantly higher with the NCEP-ATP III diagnostic criteria than with WHO and IDF criteria. A steady rise in the incidence of MetS was observed over the study period of 2004-2019. Among the components of MetS, the incidence of central obesity, elevated TG levels, and low HDL-C were found to be higher in the female population than in males, whereas the incidence of hypertension was higher in males. Stringent lifestyle measures, along with appropriate pharmacological management, might help mitigate the risks associated with MetS.

Identifiants

pubmed: 38881133
doi: 10.59556/japi.72.0563
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

39-43

Informations de copyright

© Journal of the Association of Physicians of India 2024.

Auteurs

Harshpreet Singh Tuteja (HS)

Consultant, Department of Medicine, SRS Hospital, Ambikapur, Chhattisgarh, India, Corresponding Author.

Nikhil Nassikar (N)

Associate Professor, Department of Medicine, BKL Walawalakar Medical College, Mumbai, Maharashtra, India.

Krish Panikar (K)

Resident, Department of Endocrinology, Amrita Institute, Cochin, Kerala, India.

Mangesh Tiwaskar (M)

Consultant Physician & Diabetologist, Shilpa Medical Research Centre, Mumbai, Maharashtra, India.

Sanhita Walwalkar (S)

Consultant, Dr Panikar Diabetes Care, Lilavati Hospital, Mumbai, Maharashtra, India.

Ishita Sachdev (I)

Consultant, Dr Panikar Diabetes Care, Lilavati Hospital, Mumbai, Maharashtra, India.

Sunil Kamble (S)

Consultant, Dr Kamble Diabetes Care, Lilavati Hospital, Mumbai, Maharashtra, India.

Parveen Kadir (P)

Resident, Department of Endocrine, Lilavati Hospital, Mumbai, Maharashtra, India.

Aditi Mahajan (A)

Resident, Department of Endocrine, Lilavati Hospital, Mumbai, Maharashtra, India.

Shashank Joshi (S)

Consultant, Department of Endocrine, Lilavati Hospital, Mumbai, Maharashtra, India.

Vijay Panikar (V)

Consultant and HOD, Department of Endocrine, Lilavati Hospital, Mumbai, Maharashtra, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH